Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-385 in Healthy Volunteers
NCT04075643Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of carvedilol in hypertension (HTN) and heart failure (HF) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under Curve last at 48 hours and Maximum Plasma Concentration at 48 hours. Started Sep 2019; status: completed.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT04075643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075643.